Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

Abstract Background The advances in colorectal cancer (CRC) treatment include the identification of deficiencies in Mismatch Repair (MMR) pathway to predict the benefit of adjuvant 5-fluorouracil (5-FU) and oxaliplatin for stage II CRC and immunotherapy. Defective MMR contributes to chemoresistance...

Full description

Bibliographic Details
Main Authors:	Helena de Castro e Gloria, Laura Jesuíno Nogueira, Patrícia Bencke Grudzinski, Paola Victória da Costa Ghignatti, Temenouga Nikolova Guecheva, Natalia Motta Leguisamo, Jenifer Saffi
Format:	Article
Language:	English
Published:	BMC 2021-04-01
Series:	BMC Cancer
Subjects:	Colorectal cancer Mismatch repair 5-fluorouracil PARP Olaparib
Online Access:	https://doi.org/10.1186/s12885-021-08188-7

Similar Items

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
by: Isabella Faraoni, et al.
Published: (2019-09-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
by: Baldwin P, et al.
Published: (2018-11-01)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
by: De Felice F, et al.
Published: (2017-03-01)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
by: LeVee A, et al.
Published: (2021-09-01)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
by: Montemorano L, et al.
Published: (2019-12-01)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
by: Jean-David Fumet, et al.
Published: (2020-08-01)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
by: Hye Jeong Park, et al.
Published: (2018-05-01)

The combination of olaparib and camptothecin for effective radiosensitization
by: Miura Katsutoshi, et al.
Published: (2012-04-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
by: Setor Amuzu, et al.
Published: (2021-03-01)

Prognostic Significance of the Mismatch Repair Gene in Colorectal Cancer Patients Treated with 5-Fluorouracil Chemotherapy.
by: Kanet Kanjanapradit, et al.
Published: (2011-02-01)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
by: Ana Beatriz Varanda, et al.
Published: (2020-07-01)

Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors
by: Cheng-Zhi Gao, et al.
Published: (2019-01-01)

Long-Term Follow-Up of a Female Patient Treated with Olaparib—Hope for a Long Life without Relapse?
by: Mateusz Kozłowski, et al.
Published: (2021-03-01)

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
by: R. de Haan, et al.
Published: (2019-09-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
by: Paul Lesueur, et al.
Published: (2019-03-01)

Olaparib is effective in combination with, and as maintenance therapy after, first‐line endocrine therapy in prostate cancer cells
by: Gertrud E. Feiersinger, et al.
Published: (2018-04-01)

The PARP Inhibitor Olaparib Modulates the Transcriptional Regulatory Networks of Long Non-Coding RNAs during Vasculogenic Mimicry
by: Mónica Fernández-Cortés, et al.
Published: (2020-12-01)

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report
by: Rosa Montero-Macias, et al.
Published: (2021-04-01)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
by: Kamila Burdova, et al.
Published: (2019-10-01)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
by: Sabrina Borchert, et al.
Published: (2019-01-01)

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
by: Liying Ma, et al.
Published: (2020-10-01)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
by: Yi Ma, et al.
Published: (2018-10-01)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations
by: Chiao-En Wu, et al.
Published: (2021-04-01)

HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells
by: Sabine Hombach‐Klonisch, et al.
Published: (2019-02-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials
by: Alecu I, et al.
Published: (2018-02-01)

PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors
by: Valentina Perini, et al.
Published: (2020-11-01)

Efeito citotóxico do Olaparib em células de câncer colorretal : estudo da influência de defeitos genéticos
by: Sousa, Fabrício Garmus
Published: (2012)

Efeito citotóxico do Olaparib em células de câncer colorretal : estudo da influência de defeitos genéticos
by: Sousa, Fabrício Garmus
Published: (2012)

Efeito citotóxico do Olaparib em células de câncer colorretal : estudo da influência de defeitos genéticos
by: Sousa, Fabrício Garmus
Published: (2012)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
by: Brian T. Burgess, et al.
Published: (2020-02-01)

Synergy between Non-Thermal Plasma with Radiation Therapy and Olaparib in a Panel of Breast Cancer Cell Lines
by: Julie Lafontaine, et al.
Published: (2020-02-01)

PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells
by: Michelle Schacke, et al.
Published: (2019-01-01)

Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS
by: Roberta Ottria, et al.
Published: (2019-03-01)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
by: Miriam K. Gomez, et al.
Published: (2020-06-01)